ReviewOncotarget2026
Re-expression of MHC-I to treat CNS cancers.
Review in Oncotarget, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Copyright: © 2026 Yuzhalin. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Immunologically “cold” malignant tumors of the central nervous system (CNS) evade immune surveillance largely through downregulation or loss of major histocompatibility complex class I (MHC-I), impairing CD8+ T cell-mediated elimination and contributing to poor prognosis. I discuss multiple strategies to restore MHC-I expression in brain cancers, including epigenetic modulation with histone deacetylase (HDAC) and DNA methyltransferase inhibitors, adeno-associated virus (AAV)-based gene therapy for direct human leukocyte antigen (HLA) class I or transcription factor delivery, and modulation of the tumor microenvironment to enhance antigen presentation. In addition, targeting autophagy and addressing genetic HLA losses are discussed as critical considerations. Effective MHC-I restoration may require integrated approaches that also enhance antigen processing and neoantigen presentation. Overcoming CNS-specific barriers and combining MHC-I re-expression with immunotherapy and chemoradiotherapy could unlock new therapeutic avenues against CNS malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.